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Identity 
Other names: GPR30; CEPR; CMKRL2; DRY12; 
FEG-1; GPCR-Br; LERGU; LERGU2; LyGPR; mER 




GPR30 is an estrogen-responsive GPCR (7-
transmembrane G protein-coupled receptor). 
Description 
The open reading frame of GPR30 is encoded by a 
single exon (1125 bp) located at chromosome 7p22.3. 
Transcription 
GPR30 mRNA is about 3.0 kb in human with an 1125 
bp open reading frame. 
Protein 
Description 
The gene encodes a 7-transmembrane G protein-
coupled receptor (GPCR) of 375 amino acids. 
 
Expression 
GPR30 is widely express throughout the body. 
Localisation 
Predominantly in the Endoplasmic Reticulum. 
Function 
Rapid and transcriptional responses to estrogen. 
GPR30 is a 7-transmembrane G protein-coupled 
receptor (GPCR) that has been shown to be an estrogen 
responsive receptor, expressed predomin-antly in the 
endoplasmic reticulum. Signaling occurs via 
heterotrimeric G protein activation resulting in matrix-
metalloproteinase activation, release of heparin-binding 
EGF and transactivation of EGFR with subsequent 
MAPK and Akt activation. Calcium mobilization has 
also been reported in multiple cell types including 
neurons. This protein plays a role in the rapid non-
genomic signaling events often seen following 
stimulation with estrogen. Transcriptional activation 
has also been reported secondary to kinase activation. 
Actions of GPR30 can occur in parallel to those 
mediated by ERalpha and ERbeta in cells where 
multiple receptor are expressed, or in the absence of 
ERalpha and ERbeta. Note that GPR30 does not appear 




Diagram from Entrez Gene. 
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Alternate transcriptional splice variants (involving the 5' UTR region of the gene) have been characterized. 
Diagram from Entrez Gene. 
 
Cellular activation by GPR30 and classical estrogen receptors (ERs). Receptor agonists and antagonists (indicated by upward and 
downward arrows, respectively) are shown for the indicated receptor (Tam, tamoxifen; G-1, GPR30-selective agonist; G15, GPR30-
selective antagonist). Nuclear estrogen receptors classically mediate gene regulation although they can also mediate rapid signaling 
through kinases (not shown). GPR30 is found predominantly in the endoplasmic reticulum and mediates cell activation at least in part 












Expression levels correlated with HER-2/neu,  
tumor size and the presence of metastatic disease in 
breast cancer. Expression correlated with survival and  
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high-risk disease in endometrial cancer. GPR30 
mediates estrogen-dependent responses in breast, 
endometrial and ovarian cancer cell lines including 
proliferation and migration. 
Other 
Note 
GPR30 has been implicated to play a role in estrogen-
induced thymic atrophy, estrogen-media-ted 
amelioration of autoimmune encephalomyelitis, 
depression, pain, vascular function and oocyte 
maturation. 
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